Home › Companies › TGTX

Tg Therapeutics

TGTX Rare disease Lead: Approved 2 Biotech Distilled articles ↓

Neurology Cell Protein

Most recent annual filing: 2026-02-27

Pipeline (4 active programs)

BRIUMVI

ublituximab-xiiy

Protein Target: CD20

Relapsing Forms of Multiple Sclerosis Approved intravenous Neuraxpharm
Myasthenia Gravis Phase 1

ublituximab

Protein Target: CD20

Relapsing Forms of Multiple Sclerosis Phase 3 subcutaneous

azercabtagene zapreleucel

azer-cel

Cell Target: CD19

Progressive Multiple Sclerosis Phase 1 Precision

Biotech Distilled coverage (2)

Articles open on Substack. Some deep dives are subscriber-only.